SPRB vs. IPA, VIRX, FBIO, DARE, ACXP, BCTX, CASI, MRKR, THTX, and APLM
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), Fortress Biotech (FBIO), Daré Bioscience (DARE), Acurx Pharmaceuticals (ACXP), BriaCell Therapeutics (BCTX), CASI Pharmaceuticals (CASI), Marker Therapeutics (MRKR), Theratechnologies (THTX), and Apollomics (APLM). These companies are all part of the "pharmaceutical preparations" industry.
ImmunoPrecise Antibodies (NASDAQ:IPA) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 6.8% of ImmunoPrecise Antibodies shares are held by insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ImmunoPrecise Antibodies has a net margin of -60.23% compared to ImmunoPrecise Antibodies' net margin of -461.67%. Spruce Biosciences' return on equity of -26.54% beat ImmunoPrecise Antibodies' return on equity.
In the previous week, Spruce Biosciences had 18 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 19 mentions for Spruce Biosciences and 1 mentions for ImmunoPrecise Antibodies. Spruce Biosciences' average media sentiment score of 1.43 beat ImmunoPrecise Antibodies' score of 0.27 indicating that ImmunoPrecise Antibodies is being referred to more favorably in the media.
ImmunoPrecise Antibodies has higher revenue and earnings than Spruce Biosciences. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
ImmunoPrecise Antibodies has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500.
Spruce Biosciences received 31 more outperform votes than ImmunoPrecise Antibodies when rated by MarketBeat users. However, 87.50% of users gave ImmunoPrecise Antibodies an outperform vote while only 63.33% of users gave Spruce Biosciences an outperform vote.
ImmunoPrecise Antibodies presently has a consensus target price of $7.00, indicating a potential upside of 484.26%. Spruce Biosciences has a consensus target price of $5.67, indicating a potential upside of 655.56%. Given ImmunoPrecise Antibodies' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than ImmunoPrecise Antibodies.
Summary
ImmunoPrecise Antibodies beats Spruce Biosciences on 9 of the 17 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
